Home
Products
Fustin
| Product Name | Fustin |
| Price: | Inquiry |
| Catalog No.: | CN05458 |
| CAS No.: | 20725-03-5 |
| Molecular Formula: | C15H12O6 |
| Molecular Weight: | 288.3 g/mol |
| Purity: | >=98% |
| Type of Compound: | Flavonoids |
| Physical Desc.: | Powder |
| Source: | The peels of Toxicodendron vernicifluum (Stokes) F. Barkley |
| Solvent: | Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc. |
| SMILES: | Oc1ccc2c(c1)O[C@@H]([C@H](C2=O)O)c1ccc(c(c1)O)O |
| Contact us | |
|---|---|
| First Name: | |
| Last Name: | |
| E-mail: | |
| Question: | |
| Description | Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) is a potent amyloid β (Aβ) inhibitor. Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) increases the expression of acetylcholine (ACh) levels, choline acetyltransferase (ChAT) activity, and ChAT gene induced by Aβ (1-42). Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) decreases in acetyl cholinesterase (AChE) activity and AChE gene expression induced by Aβ (1-42). Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) increases muscarinic M1 receptor gene expression and muscarinic M1 receptor binding activity. Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) can be used for Alzheimer's disease research[1]. |
| In Vivo | Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) (50-100 mg/kg; p.o.; daily, for 11days; Aβ-treated C57BL/6 mice) attenuates Aβ (1-42)-induced impairments in conditioned fear learning and passive avoidance behavior[1]. Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) (50-100 mg/kg; p.o.; daily, for 11days; Aβ-treated C57BL/6 mice) alters Aβ (1-42)-induced changes in ACh level and AChE and ChAT activity and gene expression[1]. Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) (50-100 mg/kg; p.o.; daily, for 11days; Aβ-treated C57BL/6 mice) increases Aβ (1-42)-induced reduction in M1 receptor mRNA and protein expression in Aβ-treated C57BL/6 mice. Fustin increases p-ERK and p-CREB expression in Aβ-treated C57BL/6 mice[1]. Animal Model: Aβ-treated C57BL/6 mice[1] Dosage: 50 and 100 mg/kg Administration: Oral administration;daily, for 11days Result: Decreased freezing response in Aβ-treated C57BL/6 mice. Animal Model: Aβ-treated C57BL/6 mice[1] Dosage: 50 and 100 mg/kg Administration: Oral administration;daily, for 11days Result: Increased the expression of Ach, ChAT gene and ChAT activity. Decreased the expression of AChE gene and AChE activity. Animal Model: Aβ-treated C57BL/6 mice[1] Dosage: 50 and 100 mg/kg Administration: Oral administration;daily, for 11days Result: Increased gene expression of M2- , M3- ,M4-, M5-, α4β, α7-receptor, p-ERK and p-CREB. |
| Density | 1.6±0.1 g/cm3 |
| Boiling Point | 644.2±55.0 °C at 760 mmHg |
| Flash Point | 249.2±25.0 °C |
| Exact Mass | 288.063385 |
| PSA | 107.22000 |
| LogP | 1.38 |
| Vapour Pressure | 0.0±2.0 mmHg at 25°C |